Efgartigimod for Stiff Person Syndrome
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a drug called efgartigimod to see if it can reduce muscle stiffness and spasms in people with Stiff Person Syndrome. If you have GAD antibodies and stable symptoms, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stiffness in your legs or trunk muscles and muscle spasms you can't control.
- You have GAD antibodies in your blood or spinal fluid (a marker of stiff person syndrome).
- You have been on stable doses of muscle relaxant medications for at least 2 months.
- If you are a woman able to get pregnant, you must use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an intravenous immune globulin (a purified blood protein that regulates immunity) can reduce muscle stiffness and spasms in adults with stiff person syndrome. If it works, this treatment could offer a new option for people whose muscles become abnormally rigid and painful.
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
This trial tests if the drug efgartigimod can help people with Guillain-Barré Syndrome (GBS). If you have had GBS symptoms for less than two weeks and your weakness is moderate to severe, this study may be an option.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests a medication called efgartigimod that may help people with Sjogren's disease who have nerve damage causing numbness, tingling, or weakness. The drug works by blocking certain antibodies that are thought to attack the nerves. It aims to improve nerve symptoms and quality of life.
Hear when a new Stiff Person Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.